ZIMMER BIOMET HOLDINGS, INC. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Zimmer Biomet reported Q3 2026 net sales of $2.063 billion (+3.7% constant currency; +3.1% reported). Diluted EPS fell 13.8% to $1.00 reported but adjusted EPS held flat at $1.90 vs. prior year. The company raised full-year 2026 organic constant-currency revenue guidance to 3.0%–3.5% (from 2.25%–3.25%) and adjusted EPS guidance to $8.50–$8.60 (from $8.47–$8.59). Key drivers: Hips (+7.0% constant currency), S.E.T. (+7.1%), and Technology Data/Bone Cement/Surgical (+13.0%). Knees contracted -2.6%. Operating cash flow reached $560M in Q3; nine-month free cash flow was $926.5M.
Why this rating
Modest revenue beat and guidance lift signal operational traction (Hips, S.E.T. growing double-digit), but Knees decline (-2.6%) and 2-quarter guidance range narrow raise offset enthusiasm. At $18B market cap, ~$62M organic growth acceleration (3.5% vs prior 3.25% = +10bps, or ~$220M incremental revenue) is meaningful but not transformational. Adjusted EPS guidance midpoint raised slightly, signaling confidence. Event is real progress but not trajectory-changing.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.